grant
Chemotherapy induced MASP activation and ovarian cancer metastasis
Organization UNIVERSITY OF MARYLAND BALTIMORELocation BALTIMORE, UNITED STATESPosted 1 Feb 2025Deadline 31 Jan 2030
NIHUS FederalResearch GrantFY2026AdhesionsAngiogenesis AntagonistsAngiogenesis BlockersAngiogenesis InhibitorsAngiogenetic AntagonistsAngiogenetic InhibitorsAngiogenic AntagonistsAngiogenic InhibitorsAngiostatic AgentsAnti-Angiogenetic AgentsAnti-Angiogenic AgentsAnti-Angiogenic DrugsAnti-Cancer AgentsAnti-VEGFAnti-VEGF Humanized Monoclonal AntibodyAnti-VEGF RhuMAbAntiangiogenesis AgentsAntiangiogenic AgentsAntiangiogenic DrugsAntimitotic AgentsAntimitotic DrugsAntimitoticsAntineoplastic AgentsAntineoplastic DrugsAntineoplasticsAscitesAssayAutomobile DrivingBioassayBiological AssayCancer DrugCancer PatientCancer cell lineCell BodyCell SurvivalCell ViabilityCell divisionCell surfaceCellsCessation of lifeChemoresistanceClinicalClinical ManagementCombined Modality TherapyDNA mutationDataDeathDebulkingDevelopmentDiagnosisDiseaseDisease remissionDisorderEnzyme GeneEnzymesEpithelial ovarian cancerEpitheliumFallopian TubesFemale Reproductive CancerGenesGenetic ChangeGenetic defectGenetic mutationGoalsGreater sac of peritoneumGynecologic CancerGynecological CancerHeterograftHeterologous TransplantationHumanImmunocompetentImmunotherapeutic agentIn VitroIncidenceInvadedLifeLinkMaintenanceMaintenance TherapyMalignant CellMalignant Female Reproductive System NeoplasmMalignant Gynecologic NeoplasmMalignant Gynecologic TumorMalignant Ovarian NeoplasmMalignant Ovarian TumorMalignant Tumor of the Female Reproductive SystemMalignant Tumor of the OvaryMalignant neoplasm of ovaryMammalian OviductsMediatingMembraneMesothelial CellMesotheliumMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsMicrotubular Function InhibitorsMitosis Inhibitor AgentsMitosis Inhibitor DrugsMitosis InhibitorsMitotic Inhibitor AgentsMitotic Inhibitor DrugsMitotic InhibitorsMoAb VEGFModern ManMolecularMonoclonal Antibody Anti-VEGFMultimodal TherapyMultimodal TreatmentMurineMusMutationNeoplasm MetastasisNeoplastic Disease Chemotherapeutic AgentsNeovascularization InhibitorsOrganOvarianOvarian TumorOvary CancerOvary NeoplasmsOvary TumorPARP InhibitorPARP-1 inhibitorPARPiPathway interactionsPatientsPeritonealPeritoneal CavityPlatinumPlatinum BlackPoly(ADP-ribose) Polymerase InhibitorPoly(ADP-ribose) polymerase 1 inhibitorPrimary NeoplasmPrimary TumorProcessPrognosisPropertyPt elementRNA SeqRNA sequencingRNAseqRecombinant Humanized Anti-VEGF Monoclonal AntibodyRecombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth FactorRecurrenceRecurrentRecurrent NeoplasmRecurrent tumorRemissionResearchResistanceRhuMAb VEGFRoleSalpinxSecondary NeoplasmSecondary TumorSerine EndopeptidasesSerine ProteaseSerine Protein HydrolasesSerine ProteinasesSerousSignal PathwaySignaling MoleculeSiteSurfaceTestingTherapeuticTumor CellTumor Cell LineTumor DebulkingTumor PromotionTumor-Specific Treatment AgentsUterine TubesXenograftXenograft procedureXenotransplantationabdominal dropsyanti-cancer drugantiangiogenicbevacizumabcancer cellcancer metastasiscancer sub-typescancer subtypeschemoresistantchemotherapychemotherapy resistancechemotherapy resistantcombination therapycombined modality treatmentcombined treatmentcytoreductive surgerydevelopmentaldifferential expressiondifferentially expresseddrivingexperienceexperimentexperimental researchexperimental studyexperimentsgenome mutationgynecologic malignancygynecological malignancyhydroperitoniahydrops abdominisimmune competentimmune drugsimmune-based therapeuticsimmunologic therapeuticsimmunotherapeuticsimmunotherapy agentimprovedin vivointervention designintraperitonealmembrane structuremetastatic processmolecular targeted therapeuticsmolecular targeted therapiesmolecular targeted treatmentmortalitymouse modelmulti-modal therapymulti-modal treatmentmurine modelneoplasm recurrenceneoplastic cellnovelovarian cancerovarian neoplasmoviductpathwayperitoneal dropsyperitoneal exudatepre-clinicalpreclinicalprogramsresistantresponse to therapyresponse to treatmentrhuMabVEGFsocial rolespheroidssurgical cytoreductiontaxanetherapeutic responsetherapeutically effectivetherapy designtherapy responsetranscriptional differencestranscriptome sequencingtranscriptomic sequencingtreatment designtreatment responsetreatment responsivenesstumortumor cell metastasistumor cytoreductiontumor growthxeno-transplantxeno-transplantation
Description preview
SUMMARY
Metastasis is the leading cause of high mortality in epithelial ovarian cancer (OC) patients. The most common
and insidious OC subtype, high-grade serous ovarian cancer (HGSOC), is often diagnosed after it has already
metastasized beyond the primary tumor site. Current clinical management for HGSOC is based on cytoreductive
surgery and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click